secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001829126-25-000729
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel places UK subsidiary into CVL; to buy plogosertib, sell fadraciclib
----------------------------------------------------------------------------

- UK subsidiary Cyclacel Ltd entered creditors voluntary liquidation; joint liquidators appointed.
- Company plans to purchase plogosertib from liquidators for new oral formulation development.
- Fadraciclib program will be marketed for sale by liquidators and removed from company assets.
- Deconsolidation expected to increase stockholders' equity by approximately $5.6M in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000182912625000729/0001829126-25-000729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000182912625000729/cyclacelpharma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-000729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer